Mesoblast Chief Medical Officer Dr Fred Grossman said: “The extensive body of safety and efficacy data generated to date using remestemcel-L in children with graft versus host disease suggest that our cellular therapy could provide a clinically important therapeutic benefit in MIS-C patients, especially if the heart is involved as a target organ for inflammation. Use of remestemcel-L in children with COVID-19 builds on and extends the potential application of this cell therapy in COVID-19 cytokine storm beyond the most severe adults with acute respiratory distress syndrome.”
So exciting!
Mesoblast Chief Medical Officer Dr Fred Grossman said: “The...
-
- There are more pages in this discussion • 423 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.025(2.29%) |
Mkt cap ! $1.216B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.10 | $1.06 | $4.942M | 4.613M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 70659 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 43531 | 2 |
View Market Depth
| Last trade - 16.10pm 20/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |